Melbourne, Australia – Opyl Limited (ASX: OPL or “the Company”), a leading provider of AI-driven clinical trial design and optimisation solutions, is excited to announce the first revenue from its recently launched TrialGen platform. We are proud to welcome our inaugural customer, Brain Vector, a pioneering company in personalised mental healthcare.
Key Highlights:
Securing Our First Contract
TrialKey has secured its first contract with Brain Vector, marking a significant milestone for our TrialGen platform. This partnership is valued at up to A$30,000, with Brain Vector utilising our services across four critical areas: Competitor Analysis, Trial Design Optimisation, Probability of Success Analysis Simulation, and Reporting.
Supporting Brain Vector’s Mission
Brain Vector is a leader in personalised mental healthcare, and we are excited to support their mission through our AI-driven solutions. TrialGen will provide Brain Vector with:
- Competitor Analysis: Identifying competitor trials using Brain Vector technology or related therapies and conducting in-depth analysis of technology usage, methodologies, and outcomes.
- Trial Design Optimisation: Crafting comprehensive trial designs to enhance success probabilities, including detailed protocols, trial arms, and participant criteria.
- Probability of Success Analysis Simulation: Simulating and estimating success probabilities, presenting probability distributions, and conducting sensitivity analysis.
- Reporting: Generating two detailed reports for each of the six trials, one investor-focused and one clinical-focused.
Risk-Sharing Agreement
In an innovative risk-sharing agreement, TrialKey will only receive payment if Brain Vector secures their next round of funding. This underscores our commitment to supporting our clients’ success while aligning our interests.
Significance for Opyl
This engagement with Brain Vector validates the value and effectiveness of our TrialGen platform in real-world clinical settings. By providing data-driven insights and optimisation strategies, TrialGen aims to enhance the success rates of clinical trials and support the development of groundbreaking therapies.
Executive Chairman’s Perspective
Opyl Executive Chairman Saurabh Jain said, “Our partnership with Brain Vector marks a significant milestone with the first revenue generated from the TrialGen platform. This collaboration underscores the immense potential and transformative impact of our AI-driven clinical trial solutions in real-world settings. By joining forces with Brain Vector, a leader in personalised mental healthcare, we are poised to drive groundbreaking advancements in mental health therapies. This partnership not only validates our innovative approach but also opens considerable future opportunities to enhance the success rates of clinical trials and improve patient outcomes globally.”
Brain Vector’s Perspective
Brain Vector CEO Dr. Stephane Verhaeghe added, “The integration of Opyl’s AI-driven TrialGen platform into our clinical trial processes represents a significant step forward in our mission to revolutionise mental health therapies. By leveraging Opyl’s expertise in clinical trial design and optimisation, we aim to enhance the efficacy and success rates of our innovative VRPME™ technology. This collaboration opens up substantial opportunities for both companies to make a lasting impact on mental health treatment and improve the quality of life for countless individuals.”
About Brain Vector
Brain Vector is at the forefront of mental health therapy with its proprietary VRPME™ (Virtual Reality Positive Memory Enhancement) technology. This cutting-edge approach promotes psychological well-being by helping patients relive positive experiences tailored to their unique life journeys. Brain Vector’s VRPME™ is developing precision therapy designed to minimise the development of mental health conditions and optimise mental performance across various fields.
Conclusion
The launch of TrialGen and our partnership with Brain Vector marks a significant milestone for Opyl. We are committed to leveraging AI technology to transform clinical research and improve patient outcomes. Stay tuned for more updates as we continue to innovate and lead the way in AI-driven clinical research solutions.
